Drug Analysis: Dulera

Drug Analysis: Dulera

  • February 2018 •
  • 17 pages •
  • Report ID: 5367946 •
  • Format: PDF
Drug Overview
Dulera ([mometasone + formoterol]; Merck and Co) is an oral inhalation drug that contains a combination of mometasone (an inhaled corticosteroid) and formoterol (a long-acting beta 2 agonist). Mometasone is a glucocorticoid receptor agonist with potent anti-inflammatory activity.

Formoterol fumarate is a beta-2 adrenergic receptor agonist and acts as a bronchodilator. Dulera is approved in the US where it is indicated for the treatment of asthma in adults and adolescents aged 12 years and above.